HARP News and Press, Harpoon Therapeutics Inc. From 12/12/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Evgeny Karandaev/ShutterStock.com Reborn Coffee (NASDAQ: REBN ) stock is heating up on Monday as investors take note of the California coffee company’s shares. With that comes heavy trading of REB...

Nano cap biotech Harpoon Therapeutics ( NASDAQ: HARP ) added ~122% in the morning hours Monday after the company disclosed updated interim data from its Phase 1 clinical trial for investigational cancer therapy HPN217 in relapsed/refractory multiple myeloma (RRMM). The company sai...

Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma 77% (10/13) objective response rate (ORR) observed across highest doses (12 and 24 mg) Responses were durable, with many patients ...

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a conference call and webcast to review updated interim results of its Phase 1 HPN...

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare ...

Harpoon Therapeutics press release ( NASDAQ: HARP ): Q3 GAAP EPS of -$0.35 beats by $0.20 . Revenue of $13.6M (+203.6% Y/Y) beats by $7.25M . Harpoon ended the third quarter of 2022 with $66.1M in cash, cash equivalents and marketable securities, compared to $1...

HPN217 (BCMA) interim data update at ASH 2022; HPN328 (DLL3) exploring dosing regimens and HPN601 (EpCAM) expected to enter the clinic in 2023 Strategic realignment to focus resources on ongoing clinical programs; restructuring workforce to support prioritized clinical dev...

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will present updated interim data from its Phase 1 clinical trial evaluating single...

After AstraZeneca ( AZN ) unit Alexion ( AZN ) agreed to acquire nano-cap LogicBio ( LOGC ), paying over 660% premium on Monday, Cantor sees further acquisitions for smaller cap firms where valuations have come under pressure despite their attractive assets/ platforms. ...

Harpoon Therapeutics ( NASDAQ: HARP ) has announced the appointment of Luke Walker, M.D., as Chief Medical Officer. Dr. Walker will lead the clinical development strategy and its execution for Harpoon Therapeutics and the product candidates derived from the company&#x...